Vion has entered phase III trial with it's anti cancer drug Cloretazine in combination with cytarabine in the treatment of relapsed acute myelogenous leukemia.
Cloretazine is a DNA alkylating agent that transfers an alkyl group to it's target within the cell. This leads to DNA strand breakage especially in cells that are replicating (cancer cells) and leads to cell death. These cells seem to lose the ability to initiate DNA repair as well.
VION is trading at $1.79. I could see this stock reaching 5 dollars.
About VION:
The Company is a development stage company engaged in the development of novel therapeutics for the treatment of cancer. Its portfolio of potential products consists of two distinct small molecule anticancer agents in clinical development, and additional small molecules and a drug delivery system in preclinical development. The Company's product development programs are based on technologies that it licenses from Yale University and other cancer research centers. The Company's product development strategy consists of two approaches. First, it engages in product development with respect to novel anticancer therapeutics through in-house preclinical and clinical development and through collaboration with academic institutions. Second, depending on financial and pharmaceutical market conditions and required resources, the Company determines the method and/or partnership to develop, and eventually market, its products.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment